Activated B-cell (ABC) DLBCL patients bearing Nuclear Factor-κappa light chain enhancer of Β cells (NF-κB) activating mutations, and Germinal Center (GC) DLBCL patients with BCL2-activating mutations have particularly poor prognosis [11]. Here, BCL2 is linked to diffuse large B-cell lymphoma.